DXP Enterprises (NASDAQ:DXPE) versus Cyclacel Pharmaceuticals (NASDAQ:BGMS) Head to Head Survey

DXP Enterprises (NASDAQ:DXPE) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both industrials companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Earnings & Valuation

This table compares DXP Enterprises and Cyclacel Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DXP Enterprises	$2.02 billion	1.18	$88.68 million	$6.01	25.50
Cyclacel Pharmaceuticals	$750,000.00	6.27	-$3.00 million	($3.64)	-0.20

DXP Enterprises has higher revenue and earnings than Cyclacel Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than DXP Enterprises, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for DXP Enterprises and Cyclacel Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DXP Enterprises	0	2	3	0	2.60
Cyclacel Pharmaceuticals	1	0	0	0	1.00

DXP Enterprises presently has a consensus target price of $183.00, suggesting a potential upside of 19.40%. Given DXP Enterprises’ stronger consensus rating and higher possible upside, analysts plainly believe DXP Enterprises is more favorable than Cyclacel Pharmaceuticals.

Institutional & Insider Ownership

74.8% of DXP Enterprises shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 22.0% of DXP Enterprises shares are owned by insiders. Comparatively, 23.7% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares DXP Enterprises and Cyclacel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DXP Enterprises	4.45%	18.67%	5.66%
Cyclacel Pharmaceuticals	-118.27%	-31.60%	-27.72%

Volatility & Risk

DXP Enterprises has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.44, indicating that its share price is 144% less volatile than the S&P 500.

Summary

DXP Enterprises beats Cyclacel Pharmaceuticals on 11 of the 13 factors compared between the two stocks.

About DXP Enterprises

DXP Enterprises, Inc. is a distributor of industrial products and provider of related services. It supplies maintenance, repair and operating products, including bearings, power-transmission components, safety equipment and other industrial supplies to customers in a range of industries. The company also provides pump and rotating-equipment services, such as pump repair and packaged pumping systems, as well as supply-chain services that support customers’ procurement and inventory-management needs.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of cancer. Its research programs are designed to target key proteins involved in tumor-cell growth, division and survival, with the goal of addressing cancers that have limited treatment options. The company’s pipeline has included fadraciclib (CYC065), an investigational selective cyclin-dependent kinase 2 inhibitor, and sapacitabine (CYC682), an oral nucleoside analog studied in several oncology indications.